Dyadic International (NASDAQ:DYAI) Shares Cross Above Fifty Day Moving Average - Should You Sell?

Dyadic International, Inc. (NASDAQ:DYAI - Get Free Report) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $1.56 and traded as high as $1.99. Dyadic International shares last traded at $1.73, with a volume of 171,662 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a "buy" rating and set a $6.00 price objective on shares of Dyadic International in a research note on Thursday, November 14th.

Dyadic International Stock Performance

The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.54. The stock's 50 day simple moving average is $1.57 and its 200 day simple moving average is $1.39.

Dyadic International (NASDAQ:DYAI - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.06. Dyadic International had a negative net margin of 188.09% and a negative return on equity of 149.16%. The company had revenue of $1.96 million for the quarter, compared to the consensus estimate of $1.05 million. During the same period last year, the firm posted ($0.06) EPS. On average, research analysts expect that Dyadic International, Inc. will post -0.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Dyadic International stock. Chapin Davis Inc. increased its position in Dyadic International, Inc. (NASDAQ:DYAI - Free Report) by 2.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 868,301 shares of the biotechnology company's stock after acquiring an additional 21,000 shares during the period. Chapin Davis Inc. owned approximately 2.97% of Dyadic International worth $903,000 at the end of the most recent reporting period. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

Dyadic International Company Profile

Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.